Whitepapers/App Notes/Posters

Scientific briefing: Formulation-Monodisperse CR quetiapine microspheres

Posted: 4 August 2021 | | No comments yet

Adare’s Optimµm® technology offers a unique and efficient method of fabricating monodisperse microparticles at reduced development time.

The study herein uses Adare technology to fabricate monodisperse quetiapine microparticles to investigate the effects of formulation and size on the release profile of the API.

    To read this scientific briefing in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of ADARE Pharma Solutions

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.